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Purpose: To evaluate the incidence, treatment and clinical outcomes of tuberculosis pleuritis at a 
hospital in the state of Penang, Malaysia. 
Methods: A retrospective study was conducted in Hospital of Penang, Malaysia. Patient records were 
reviewed retrospectively to identify patients with confirmed diagnosis of tuberculous pleuritis from 
January 2006 to December 2008. Chest x-ray (CXR) and pleural biopsy were carried out on all patients. 
Directly observed therapy (DOT) was given to all patients. Data were analyzed using SPSS version 16.  
Results: Of 1548 tuberculosis cases, 80 (5.2 %) patients had tuberculous pleuritis. The mean age of 
the patients was 35.4 ± 12.87 years, with a male to female ratio of 3.4:1. Ethnically, a plurality (n = 30, 
37.7 %) of cases among tuberculosis pleuritis patients were Chinese, followed by Malay (31.2 %). Out 
of the 80 patients with tuberculous pleuritis, 10 (12.5 %)   also had diabetes mellitus, and 8 (10.0 %)  
HIV/AIDS. Fever, cough, chest pain and shortness of breathing were the most frequently reported 
symptoms. Treatment success rate was 1.558 times higher among TB group than pleuritis TB group 
(Odds ratio, 95 % CI, 1.06 – 2.59, p = 0.025).  
Conclusion: The incidence of TB pleuritis was gender- and race-related, with DM and HIV the most 
commonly reported risk factors. Treatment success rate was higher among pulmonary TB group than in 
those with TB pleuritis (extra pulmonary TB). 
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Tuberculosis (TB) is a leading source of 
morbidity and mortality throughout the world. It is 
estimated that in 2011, there was a total of 8.7 
million new cases and 1.4 million deaths from TB 
[1]. Although the African region has the highest 
estimated incidence (356 per 100,000 
populations per year), the majority of patients 
with TB live in the most populous countries of the 
Asian subcontinent, which accounts for nearly 
half of the new cases that arise yearly [2]. The 
frequency of pleural involvement in TB has been 
variously reported to range from 4 % in United 
States to 23 % in Spain) [3,4]. 
 
TB pleural effusion is the second most common 
form of extrapulmonary tuberculosis (EPTB), only 
less frequent than lymph node TB. TB pleural 
effusion is increasingly recognized, even in 
developed nations [5], as the incidence of EPTB 
has more than doubled following HIV pandemic. 
The incidence of TB pleural effusions in human 
immunodeficiency virus / acquired immuno-
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deficiency syndrome (HIV/AIDS) has been 
variously reported to range from 15 to 90 % with 
effusion being more common in patients with 
higher CD4+ counts [6-8].  
 
In some parts of the world, tuberculosis remains 
the most frequent cause of pleural effusion in the 
absence of an obvious pulmonary lesion. 
Diagnosis of tuberculosis in pleural effusion can 
be made by pleural fluid culture. Pleural biopsy 
can also be used to diagnose TB. When 
microscopic examination of biopsy specimen is 
combined with culture, diagnosis can be made in 
90 % of patients, especially with the use of 
multiple biopsies [9]. 
 
Malaysia, a multicultural and multiethnic country, 
has a population slightly above 26 million and an 
area of 33,000 km2. Tuberculosis is among the 
top five communicable diseases in the country 
with an incidence rate of 62.56 per 100,000 and 
mortality rate of 5.37 per 100,000 [10]. The State 
of Penang is the eighth most populous state in 
Malaysia and among the top five states with the 
highest tuberculosis burden [10]. Pulmonary 
tuberculosis has been the disease of interest for 
researchers but little work has been done on 
extra-pulmonary tuberculosis, especially, 
tuberculous pleura. The current study was 
designed to expand the current knowledge by 
gathering baseline data on the incidence, 
diagnosis, complications, management and 
treatment outcomes of tuberculous pleural 




A retrospective study was conducted among 
patients visiting the respiratory clinic, Penang 
Hospital. Penang is one of thirteen states and is 
geographically situated in northern Malaysia. It is 
a multicultural state comprising of Malay (42.5 
%), Chinese (46.5 %), Indian (10.6 %) and 
minorities (0.4 %), with an estimated population 
of 1.5 million [11].  
 
A total of 1548 cases were registered for 
tuberculosis treatment from 1st January 2006 to 
December 2008 at the respiratory diseases clinic 
of Penang Hospital. This clinic is a tertiary level 
referral centre for respiratory diseases in the 
state of Penang, Malaysia. Any person with a 
respiratory problem in the state of Penang can 
attend this centre with a physician’s referral.  
  
A retrospective evaluation of the medical records 
of patients with confirmed diagnosis of 
tuberculosis pleura was carried out. From each 
medical case file, the patient’s history, physical 
parameters, chest radiographs and laboratory 
investigation was reviewed in order to obtain 
maximum information about the type and severity 
of TB. In addition, demographic factors, life style 
(smoking habit and alcohol use) and clinical 
characteristics were recorded. Among clinical 
characteristics, co-morbid medical complications 
(such as diabetes mellitus, HIV, asthma and 
chronic obstructive pulmonary disease COPD), 
medications for therapy and therapeutic 
outcomes were recorded, based on Chi-square 
and Odds ratio. The study protocol was approved 
by Clinical Research Center (CRC), Penang 





Data with quantitative variables were expressed 
by mean ± standard deviation (SD) and range 
while qualitative variables were estimated by 
frequency and percentage. Chi square (X2) and 
Odds ratio were applied to compare outcomes, 
and differences were considered significant at p 
< 0.05. The data were analyzed using SPSS® 




During the period, there was a high prevalence of 
TB pleuritis (EPTB) among all TB cases, with 
lymph node involvement (n = 109, 7.1 %) [12] 
being the commonest, followed by pleurisy (n = 
80 (5.2 %)]. Table 1 shows the demographic 
features of pleural tuberculosis; it was more 
prevalent among younger age groups, (n = 60, 
75.0 %), i.e., < 46 years. The mean age of the 
study subjects was 35.4 ± 12.9 (range 5 - 71 
years) and male to female ratio was 3.4:1. Three 
(3.8 %) of the patients with pleural TB were 
referred from Penang prison. Other co-
morbidities encountered include diabetes mellitus 
(n = 10, 12.5 %) , HIV/AIDS (n = 8, 10 %) and 
asthma (n = 2, 2.5 %). Other demographic 
parameters are shown in Table 1.  
 
A majority, 73 (91.2 %), of patients reported 
cough, 69 (86.2 %) fever, 51 (63.8 %) chest pain 
and 65 % had night sweats. Details of the 
symptoms reported are listed in Table 2. 
 
Table 3 shows chest x-ray and laboratory results. 
The disease was mostly a primary infection 
rather than a reactivation of co-existing 
pulmonary tuberculosis (past history and/or 
family history of the disease was absent in 93.8% 
of cases, and evidence of parenchyma lung 
lesions were absent in 78 % of cases). Right 
pleural effusion was slightly more common than 
left pleural effusion (48.6 % compared to 27.5 
%). Up to 3.8 % of cases had bilateral pleural 
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effusion. ESR was elevated in a majority of 
cases (> 40 mm/h in 56.2 %). Pleural biopsies for 
culture and sensitivity were positive in 49 (61.3 
%) of the cases.  
 
Table 1: Demographic profile of patients (N = 80) 
 
Parameter N (%) 
Sex ratio (M: F) 3.44: 1  
Range of age (5 - 71 years) 
Mean age 35.4 ± 12.87 
N = 80 n (%) 
Gender  
 Male 62 (77.5) 
 Female 18 (22.5) 
Race  
 Malay 25 (31.2) 
 Chinese 30 (37.7) 
 Indian 19 (23.7) 
 Indonesian 2 (2.5) 
 Others 4 (4.8) 
Age group 
            < 35 years 
 
36 (45.0) 
 35 – 45 years 24 (30.0) 
 > 45 years 20 (25.0) 
Contact history  
 Yes 3 (3.8) 
 No 75 (93.8) 
 Unknown 2 (2.5) 
Place  
 Hospital 77 (96.2) 
 Prison 3 (3.8) 
Geographical location 
            Urban Area  




Diabetes mellitus  
 Yes 10 (12.5) 
 No 70 (87.5) 
HIV  
 Yes  8 (10.0) 
 No 72 (90.0) 
Asthma 
            Yes 







            Yes 




Drinks alcohol  
 Yes 16 (20.0) 
 No 28 (35.2) 
 Unknown 29 (36.2) 
 Ex-Drinker 7 (8.8) 
Smokes  
 Yes 27 (33.8) 
 No 35 (48.8) 
 Unknown 11 (13.8) 
 Ex-Smoker 7 (8.8) 
* Chronic obstructive pulmonary disease 
 
Management and outcomes  
 
All patients received directly observed therapy 
(DOTS) from six to nine months. Two months 
ethambutol, isoniazid, rifampicin and 
pyrazinamide with four months biweekly isoniazid 
and rifampicin (2EHRZ+4H2R2) were the 
therapeutic combination used for the majority 27 
(33.8 %) of the patients. Based on the clinical 
outcomes, the duration of intensive phase was 
increased to three months in 33.2 % patients 
while the treatment success rate for TB group 
being higher than pleuritis TB group (odd ratio = 
1.558, 95% CI, 1.06 – 2.59, p = 0.025). Six (7.5 
%) patients defaulted the treatment and seven 
(8.7 %) patients were recorded as deceased 
during the course of therapy, as shown in Table 
4.  
 
Table 2: Symptoms reported by patients with 
tuberculous pleuritis (N = 80) 
 





Weight loss  
Loss of appetite 















Table 3: Laboratory test results for patients (N = 80) 
 
Test parameter   N (%) 
Chest x-ray 
Right effusion   39 (48.6) 
Left effusion   22 (27.5) 
Bilateral pleural effusion  3 (3.8) 
Consolidation   8 (10.0)  
Fibrosis   5 (6.3) 
Cavitation    3 (3.8) 
Sputum for AFB* (direct smear) 
Positive    7 (8.8) 
Negative   73 (91.2) 
Sputum for AFB (culture) 
Positive    25 (31.3) 
Negative   55 (68.7) 
Pleural biopsy of AFB direct smear 
Yes    14 (17.6)  
No    66 (82.4) 
Pleural biopsy of AFB culture sensitivity 
Yes    49 (61.3)  
No    31 (38.7) 
ESR** (mm/h) 
<20   9 (11.3) 
20–40    26 (32.5) 
>40    45 (56.2) 




There has been a rise in the prevalence of TB 
throughout the world with a propensity for 
extrapulmonary involvement. Similarly, HIV/AIDS 
cases continue to grow in numbers.  
 
in older age groups, suggesting that it may be  
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No. of TB patients 
without pleuritis 




P-value Odd Ratio 95% CI 
Successfully treated 1019 (69.5%) 48 (59.9%) 0.025 1.558 1.061 - 2.590 
Patient defaulted 81 (5.5%) 6 (7.4%) 0.533 -- -- 
Transferred out 77 (5.2%) 5 (6.2%) 0.122 -- -- 
Patient expired 120 (8.2%) 5 (6.2%) 0.668 -- -- 
Treatment continued 171 (11.5%) 16 (20.1%) 0.081 -- -- 
*A patient who has been transferred to another recording and reporting unit and for whom the treatment outcome is not known; 
** A patient who dies for any reason during the course of treatment 
 
Published data from some developed countries 
indicate that pleural tuberculosis is more frequent 
due to reactivation of the disease [3,7,8,13]. 
However the situation in developing countries is 
not clear. In the current study, we found that the 
disease is mainly a primary one rather than a 
reactivation of previous parenchymal lung 
tuberculosis. In addition, we found that pleural 
tuberculosis tends to affect younger age groups 
(< 45 years) and this more pronounded in males. 
These findings may be explained partly by the 
reduction in incidence of tuberculosis in 
developed world [5]. The unilateral tuberculous 
effusion reported in the present study confirms 
previous findings of right-sided predominance 
[3,14]. 
 
One recent study from Spain [15] that described 
pleural tuberculosis in children showed that 
history of contact with a tuberculous case was 
positive in 25.7 % of patients, but in the present 
study, we found only 3.8 % of our patients had 
such history, indicating that contact with 
tuberculous cases seems to be less evident in 
adults.  
 
Pleural tuberculosis is still a difficult disease to 
diagnose; pleural biopsy remains the gold 
standard for the diagnosis of pleural tuberculosis 
[5,6]. In a study of 42 patients with tuberculous 
effusions, closed needle biopsy achieved a 
diagnostic sensitivity of 79 % when histology and 
culture was declared a reliable tool for diagnosis 
[16]. Seibert et al reported a yield of 66.7 % from 
closed pleural biopsy cultures and 84.6 % from 
histology [7]. Pleural tissue simultaneously sent 
for mycobacterial culture in addition to histology 
may increase diagnostic yield further. The 
diagnostic yield has been reported to rise to 90% 
when closed pleural biopsies are cultured [17]. 
 
The diagnosis of tuberculous pleural effusion is 
an indication for treatment with anti-tuberculous 
chemotherapy. Standard short course 
chemotherapy with isoniazid, rifampicin, 
pyrazinamide and ethambutol followed by 4 
months of isoniazid and rifampicin is sufficient in 
the majority of cases [18]. Following the initiation 
of the standard 4-drug regimen mentioned 
above, subsequent treatment should be guided 
according to the results of drug sensitivity testing 
when they become available to the clinician. The 
incidence of residual pleural thickening and 
functional squeal can be reduced by effective 
anti-tubercular chemotherapy [19]. Although 
studies by Dutt et al supported the effectiveness 
of a 6-month regimen of isoniazid and rifampicin 
in both pulmonary and pleural disease, this is 
generally not advised due to the problems 
associated with drug resistance [8]. Paradoxical 
enlargement of the effusion has been reported 
after the commencement of anti-tuberculous 
chemotherapy similar to that seen in intra-cranial 
tuberculomas and this can require drainage, in 
some cases, for symptom relief [20].  
 
A number of studies suggest increased incidence 
of pleural involvement in AIDS cases diagnosed 
with active tuberculosis. In a study comparing 
963 HIV positive adults with pulmonary TB with 
1000 HIV negative age-matched controls, there 
was a significantly higher incidence of pleural 
effusions (16 vs. 6.8 %) [21]. In the western 
world, a study in South Carolina, USA appeared 
to show increased rates of pleural TB in AIDS 
cases (11 %) compared to non-AIDS cases (6 %) 
[22]. 
 
There is also evidence to suggest that HIV co-
infection alters the clinical presentation of TB 
pleurisy. The duration of the presenting illness 
tends to be longer in a substantial number of 
such cases compared with that seen in HIV 
negative individuals. A study from Tanzania 
found that HIV positive patients tend to present 
with more constitutional symptoms such as 
dyspnoea, fevers, night sweats, Treatment of 
tuberculous pleurisy in HIV positive co-infection 
is generally successful with a good outcome in 
most cases. In a series of 22 patients, there were 
2 deaths reported and only 1 after anti-
tuberculous chemotherapy was commenced [21]. 
The current study’s main focus is on pleurisy TB 
(EPTB) but comparison was made with PTB, to 
get a clear picture based on treatment outcomes. 
It was found that treatment completion rate was 
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48 (60.0 %), default and failure rate were 6 
(7.4%) and 5 (6.2%) respectively. Deaths were 
found in 5 (6.2 %) cases; among these 5 cases, 
4 were affected with co-morbid condition (3 
patients were pleuritis TB plys HIV/AIDS and 1 
with diabetes mellitus). Similar default and failure 
rate have been reported by Sharma et al [23]. 
 
Limitations of the study 
 
 All registered cases from January 2006 to 
December 2008 in the cited clinic were part of 
study. Due to the retrospective nature of the 
study, some social factors were, however, 





The incidence of pleura TB was higher in males 
than in females and higher in Chinese race than 
other ethnic group. Fever, cough, chest pain, 
shortness of breathing, night sweat were 
clinically proven symptoms. The study confirms 
early detection by simple tests and ensuring 
complete treatment using direct observe therapy 
short course (DOTS) strategy. DOTS strategy is 
an effective treatment modality for TB pleurisy, 
achieving a high treatment completion rate, low 
default and failure rates. HIV/AIDS, diabetes 
mellitus, COPD and asthma are co-morbidity 
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